$CAPR
CAPRICOR THERAPEUTICS, INC.

2019 Q2 Form 10-Q Financial Statement

#000114420419026041 Filed on May 14, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q4
Revenue $410.0K $230.5K $650.0K
YoY Change 1.5% -42.38% 35.42%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $830.0K $980.0K $1.100M
YoY Change -29.66% -29.5% -11.29%
% of Gross Profit
Research & Development $1.640M $1.811M $2.850M
YoY Change -51.61% -32.83% 13.1%
% of Gross Profit
Depreciation & Amortization $50.00K $43.30K $50.00K
YoY Change 25.0% 27.11% 66.67%
% of Gross Profit
Operating Expenses $2.480M $2.788M $3.950M
YoY Change -45.7% -31.78% 5.33%
Operating Profit -$2.557M
YoY Change -30.63%
Interest Expense $20.00K $40.00K $50.00K
YoY Change -171.43%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.050M -$2.520M -$3.260M
YoY Change -50.24% -31.34% -126.48%
Income Tax
% Of Pretax Income
Net Earnings -$2.050M -$2.519M -$3.260M
YoY Change -50.29% -31.38% -126.48%
Net Earnings / Revenue -500.0% -1092.97% -501.54%
Basic Earnings Per Share
Diluted Earnings Per Share -$592.5K -$766.0K -$1.048M
COMMON SHARES
Basic Shares Outstanding 34.68M 33.66M 31.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.890M $7.170M $7.256M
YoY Change -52.25% -45.54% -48.63%
Cash & Equivalents $5.890M $7.170M $4.259M
Short-Term Investments $0.00 $0.00 $2.997M
Other Short-Term Assets $610.0K $620.0K $1.010M
YoY Change -33.7% -45.61% -18.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $6.640M $7.904M $8.471M
YoY Change -50.96% -45.9% -46.09%
LONG-TERM ASSETS
Property, Plant & Equipment $510.0K $541.7K $574.2K
YoY Change 0.51% 0.32% 54.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $130.0K $130.0K $150.0K
YoY Change -38.1% -18.75% 50.0%
Total Long-Term Assets $670.0K $713.5K $775.8K
YoY Change -14.75% -8.53% 38.25%
TOTAL ASSETS
Total Short-Term Assets $6.640M $7.904M $8.471M
Total Long-Term Assets $670.0K $713.5K $775.8K
Total Assets $7.310M $8.618M $9.247M
YoY Change -48.98% -44.01% -43.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.570M $1.500M $1.260M
YoY Change 18.94% 1.35% -24.55%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.570M $1.501M $1.255M
YoY Change 18.94% 1.42% -24.87%
LONG-TERM LIABILITIES
Long-Term Debt $3.380M $3.380M $3.380M
YoY Change 0.0% 0.0% 0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $3.380M $3.376M $3.376M
YoY Change 0.11% -0.11% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.570M $1.501M $1.255M
Total Long-Term Liabilities $3.380M $3.376M $3.376M
Total Liabilities $4.940M $4.877M $4.631M
YoY Change 5.19% 0.56% -8.23%
SHAREHOLDERS EQUITY
Retained Earnings -$69.26M -$66.74M
YoY Change 25.42% 29.47%
Common Stock $73.00M $71.34M
YoY Change 260879.45% 13.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.360M $3.740M $4.616M
YoY Change
Total Liabilities & Shareholders Equity $7.310M $8.618M $9.247M
YoY Change -48.98% -44.01% -43.18%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$2.050M -$2.519M -$3.260M
YoY Change -50.29% -31.38% -126.48%
Depreciation, Depletion And Amortization $50.00K $43.30K $50.00K
YoY Change 25.0% 27.11% 66.67%
Cash From Operating Activities -$1.780M -$1.608M -$3.770M
YoY Change -51.76% -52.96% 41.2%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $10.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $2.980M $2.990M
YoY Change 49.0% -200.0%
Cash From Investing Activities $0.00 $2.985M $3.000M
YoY Change 64.75% -200.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.433M
YoY Change -39.61%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 550.0K 1.433M 510.0K
YoY Change -80.22% -42.96% -83.17%
NET CHANGE
Cash From Operating Activities -1.780M -1.608M -3.770M
Cash From Investing Activities 0.000 2.985M 3.000M
Cash From Financing Activities 550.0K 1.433M 510.0K
Net Change In Cash -1.230M 2.810M -260.0K
YoY Change 35.16% 210.0% -90.11%
FREE CASH FLOW
Cash From Operating Activities -$1.780M -$1.608M -$3.770M
Capital Expenditures $0.00 $0.00 $10.00K
Free Cash Flow -$1.780M -$1.608M -$3.780M
YoY Change -51.76% -55.39% 41.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4259266
CY2019Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2997150
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
285831
CY2019Q1 us-gaap Grants Receivable Current
GrantsReceivableCurrent
122621
CY2018Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
204868
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
425943
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
724184
CY2019Q1 us-gaap Assets Current
AssetsCurrent
7904007
CY2018Q4 us-gaap Assets Current
AssetsCurrent
8471299
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
541730
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
574206
CY2019Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
38952
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
49772
CY2019Q1 us-gaap Other Assets
OtherAssets
132816
CY2018Q4 us-gaap Other Assets
OtherAssets
151788
CY2019Q1 us-gaap Assets
Assets
8617505
CY2018Q4 us-gaap Assets
Assets
9247065
CY2019Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1462878
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1148853
CY2019Q1 capr Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
38066
CY2018Q4 capr Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
106366
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1500944
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1255219
CY2019Q1 us-gaap Other Long Term Debt
OtherLongTermDebt
3376259
CY2018Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
3376259
CY2019Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3376259
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3376259
CY2019Q1 us-gaap Liabilities
Liabilities
4877203
CY2018Q4 us-gaap Liabilities
Liabilities
4631478
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
72964900
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
71310720
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
12393
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-69258259
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66738914
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
3740302
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
4615587
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8617505
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9247065
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7170220
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7169262
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
185223
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
619427
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7355443
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7788689
CY2019Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1030232
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1030232
CY2019Q1 capr Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
7200000
CY2018Q4 capr Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
7300000
CY2019Q1 capr Amount Available Under Grant Awards
AmountAvailableUnderGrantAwards
600000
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
200000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
300000
CY2019Q1 us-gaap Depreciation
Depreciation
32476
CY2018Q1 us-gaap Depreciation
Depreciation
23241
CY2019Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
488502
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
456026
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
541730
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
574206
CY2019Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10819
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
32457
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4330
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2165
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8709
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33661346
CY2019Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
846073
CY2017Q4 capr Amount Authorized In Plans After Merger
AmountAuthorizedInPlansAfterMerger
4149710
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.45
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
223166
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
434863
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
230504
CY2018Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
400066
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1811182
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2696517
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
976490
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1389732
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
2787672
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
4086249
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2557168
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3686183
CY2019Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
37823
CY2018Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
14653
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2519345
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3671530
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12393
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8709
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2531738
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3662821
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32903837
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
3740302
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2519345
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3671530
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
43295
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26905331
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2519345
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
4615587
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1433287
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
223166
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2984757
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1811743
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
34060
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
223166
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
457612
CY2019Q1 capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
-82247
CY2018Q1 capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
-37825
CY2019Q1 capr Increase Decrease In Prepaid And Other Current Assets
IncreaseDecreaseInPrepaidAndOtherCurrentAssets
-298241
CY2018Q1 capr Increase Decrease In Prepaid And Other Current Assets
IncreaseDecreaseInPrepaidAndOtherCurrentAssets
21182
CY2019Q1 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-18972
CY2018Q1 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
61818
CY2019Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
314026
CY2018Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-87913
CY2019Q1 capr Increase Decrease In Accounts Payable And Accrued Expenses Related Party
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty
-68300
CY2018Q1 capr Increase Decrease In Accounts Payable And Accrued Expenses Related Party
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty
-104863
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1607698
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3417809
CY2019Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
15243
CY2018Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3001871
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
521678
CY2019Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
7100000
CY2016Q4 capr Disbursement Amount Under Grant Award
DisbursementAmountUnderGrantAward
3100000
CY2017Q4 capr Disbursement Amount Under Grant Award
DisbursementAmountUnderGrantAward
300000
CY2019Q1 us-gaap Payments For Royalties
PaymentsForRoyalties
20000
CY2016Q3 capr Upfront Payment
UpfrontPayment
2500
CY2017Q4 capr Reimbursed Expenses To Be Paid
ReimbursedExpensesToBePaid
50000
CY2019Q1 capr Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
38066
CY2018Q4 capr Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
106366
CY2019Q1 capr Payments For Reimbursement For Research And Development Expenses Incurred Related Party
PaymentsForReimbursementForResearchAndDevelopmentExpensesIncurredRelatedParty
100000
CY2018Q1 capr Payments For Reimbursement For Research And Development Expenses Incurred Related Party
PaymentsForReimbursementForResearchAndDevelopmentExpensesIncurredRelatedParty
200000
CY2019Q1 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
108000
CY2018Q1 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
93000
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3000000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5000000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
186386
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1433287
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2373478
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
139140
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4545097
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6882137
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7355443
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7788689
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2019Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2018Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2810346
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
906552
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33661346
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31387729
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33661346
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31387729
CY2019Q1 capr Written Notice Period
WrittenNoticePeriod
P90D
CY2019Q1 capr Compensation Receivable In Connection To Services To Be Provided
CompensationReceivableInConnectionToServicesToBeProvided
2100000
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 capr Cost For Clinical Trial Services
CostForClinicalTrialServices
42600
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
33661
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
31388
CY2019Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
220730
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
209910
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Use of Estimates</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.25in; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The most sensitive estimates relate to the recoverability and fair value of intangible assets and the assumptions used to estimate stock-based compensation expense. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
296023
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.023
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2018Q3 capr Leases Monthly Payments For Additional Twelve Months
LeasesMonthlyPaymentsForAdditionalTwelveMonths
19756
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2018Q1 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
4190
CY2019Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
63220
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
CAPRICOR THERAPEUTICS, INC.
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001133869
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q4 us-gaap Marketable Securities
MarketableSecurities
2997150
CY2018Q3 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P1Y
CY2018Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10819
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1433287
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2512618
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q1 dei Trading Symbol
TradingSymbol
CAPR
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34675234
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true

Files In Submission

Name View Source Status
0001144204-19-026041-index-headers.html Edgar Link pending
0001144204-19-026041-index.html Edgar Link pending
0001144204-19-026041.txt Edgar Link pending
0001144204-19-026041-xbrl.zip Edgar Link pending
capr-20190331.xml Edgar Link completed
capr-20190331.xsd Edgar Link pending
capr-20190331_cal.xml Edgar Link unprocessable
capr-20190331_def.xml Edgar Link unprocessable
capr-20190331_lab.xml Edgar Link unprocessable
capr-20190331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv521189_10q.htm Edgar Link pending
tv521189_ex31-1.htm Edgar Link pending
tv521189_ex31-2.htm Edgar Link pending
tv521189_ex32-1.htm Edgar Link pending
tv521189_ex32-2.htm Edgar Link pending